NCT00664378终止2 期
A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma
研究概览
简要总结
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of multiple myeloma per International Working Group (IWG) criteria
- •Have received at least 1 but no more than 4 prior lines of therapy
- •Have failed to respond to the most recently administered anti-myeloma therapy
- •Have a life expectancy of at least 3 months
- •Eastern Cooperative Oncology Group (ECOG) performance status < 3
- •At registration absolute neutrophil count > 1x10^9/L and platelet count > 50 x 10^9/L unsupported
- •At registration bilirubin less than 1.5 x upper limit of normal and transaminases less than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L
- •Written informed consent
- •Must agree to adequate contraceptive measure if indicated
排除标准
- •Patients with monoclonal gammopathy of undetermined significance
- •Known or suspected hypersensitivity to CYT997
- •Patient with uncontrolled intercurrent illness
- •Active infections or other illnesses that precludes chemotherapy administration or patient compliance.
- •Pregnant or lactating women.
- •Patients who have received any other investigational agents in the last 3 weeks prior to the start of treatment.
- •Patients with the following conditions will be excluded:
- •myocardial infarction or stroke within 6 months
- •unstable angina pectoris or acute ischemic changes on ECG
- •history of diabetic retinopathy
- •symptomatic peripheral arterial disease
- •major surgery in the last 30 days
- •Patients with uncontrolled diarrhea despite optimal medication and those with any history of acute gastrointestinal bleeding
- •Patients with a baseline prolongation of the QTc interval of Common Terminology Criteria (CTC) Grade 1 (QTc > 0.45-0.47 sec) or greater
- •Patients with impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- •left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram;
- •complete left bundle branch block;
- •obligate use of a cardiac pacemaker;
- •congenital long QT syndrome;
- •history or presence of ventricular tachyarrhythmia;
- •presence of unstable atrial fibrillation (ventricular response > 100 bpm). -Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria;
- •clinically significant resting bradycardia (< 50 bpm);
- •right bundle branch block + left anterior hemiblock (bifascicular block);
- •angina pectoris ≤ 3 months prior to starting study drug;
- •acute myocardial infarction (MI) ≤ 3 months prior to starting study drug; or
- •other clinically significant heart disease (e.g., congestive heart failure (CHF), uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen).
- •Patients currently receiving treatment with medications known to prolong the QTc interval and/or to induce Torsades de Pointes arrhythmia.
研究组 & 干预措施
I
Experimental
CYT997
干预措施: CYT997 (Drug)
结局指标
主要结局
Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma
时间窗: Baseline to study completion
The overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma once every 3 week cycle
次要结局
- Overall survival(Baseline to study completion)
- Time to disease progression(Baseline to study completion)
- Safety and tolerability(Baseline to study completion)
- Number of cycles required to achieve maximum response(Baseline to study completion)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
The Multicenter Topic TrialChronic Obstructive Pulmonary DiseaseNCT04066751University of Alabama at Birmingham
已完成
2 期
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in HondurasCOVID-19NCT04771013Universidad Católica de Honduras22
已完成
1 期
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host DiseaseGraft vs Host DiseaseNCT02923375Cynata Therapeutics Limited16
招募中
2 期
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBNCT02354014Janssen Research & Development, LLC60
已完成
1 期
Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The KneeOsteoarthritisOsteoarthritis, KneeNCT06263270Cytonics Corporation19